No­var­tis inks deal to help man­u­fac­ture J&J and Leg­end's Carvyk­ti

J&J and Leg­end have called on No­var­tis to help man­u­fac­ture Carvyk­ti, the sec­ond BC­MA CAR-T ap­proved by the FDA.

No­var­tis signed a three-year deal to man­u­fac­ture clin­i­cal batch­es of Carvyk­ti for J&J and Leg­end’s glob­al clin­i­cal de­vel­op­ment, a No­var­tis spokesper­son con­firmed on Fri­day. The batch­es will be pro­duced at No­var­tis’ cell ther­a­py site in Mor­ris Plains, NJ.

“As one of the world’s largest pro­duc­ers of med­i­cines, No­var­tis can mo­bi­lize its man­u­fac­tur­ing ca­pa­bil­i­ties on mul­ti­ple fronts,” Stef­fen Lang, No­var­tis pres­i­dent of op­er­a­tions, said in a state­ment to End­points News. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER